Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients
Kunle Odunsi(University of Chicago), Elke Jäger(Krankenhaus Nordwest), Gerd Ritter(Memorial Sloan Kettering Cancer Center), Nefertiti C. duPont(Roswell Park Comprehensive Cancer Center), Shashikant Lele(Memorial Sloan Kettering Cancer Center), Robert P. Edwards(Cancer Research UK Technology), Amy Beck, Sacha Gnjatic(Tisch Hospital), Paulette Mhawech‐Fauceglia, Lloyd J. Old(Gynecologic Oncology Group), Austin Miller(Roswell Park Comprehensive Cancer Center), Carl D. Morrison(Roswell Park Comprehensive Cancer Center), Julia Karbach(Memorial Sloan Kettering Cancer Center), Heidi Godoy(Roswell Park Comprehensive Cancer Center), Junko Matsuzaki(University of Chicago), Protul Shrikant, Antje Neumann(Krankenhaus Nordwest)
Cited by 199
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Intraepithelial CD8 <sup>+</sup> tumor-infiltrating lymphocytes and a high CD8 <sup>+</sup> /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
|Proceedings of the National Academy of Sciences|2005|2.4k
Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
|New England Journal of Medicine|2012|2.1k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k